[go: up one dir, main page]

IL137329A0 - Vla-4 antagonists - Google Patents

Vla-4 antagonists

Info

Publication number
IL137329A0
IL137329A0 IL13732999A IL13732999A IL137329A0 IL 137329 A0 IL137329 A0 IL 137329A0 IL 13732999 A IL13732999 A IL 13732999A IL 13732999 A IL13732999 A IL 13732999A IL 137329 A0 IL137329 A0 IL 137329A0
Authority
IL
Israel
Prior art keywords
vla
antagonists
Prior art date
Application number
IL13732999A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL137329A0 publication Critical patent/IL137329A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13732999A 1998-01-23 1999-01-21 Vla-4 antagonists IL137329A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1233698A 1998-01-23 1998-01-23
US11072398P 1998-12-03 1998-12-03
PCT/EP1999/000384 WO1999037605A1 (fr) 1998-01-23 1999-01-21 Antagonistes d'antigene-4 d'activation tres tardive (vla-4)

Publications (1)

Publication Number Publication Date
IL137329A0 true IL137329A0 (en) 2001-07-24

Family

ID=26683440

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13732999A IL137329A0 (en) 1998-01-23 1999-01-21 Vla-4 antagonists

Country Status (13)

Country Link
EP (1) EP1049665A1 (fr)
JP (1) JP4564654B2 (fr)
KR (1) KR20010034317A (fr)
CN (1) CN1294576A (fr)
AU (1) AU746174B2 (fr)
BR (1) BR9907733A (fr)
CA (1) CA2318639A1 (fr)
EE (1) EE200000428A (fr)
HU (1) HUP0100336A3 (fr)
ID (1) ID26665A (fr)
IL (1) IL137329A0 (fr)
NO (1) NO20003694L (fr)
WO (1) WO1999037605A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043369A1 (fr) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion aux leucocytes a mediation assuree par vla-4
PL350050A1 (en) 1999-01-22 2002-10-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
AU3246600A (en) 1999-03-01 2000-09-21 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
EP1235793A2 (fr) * 1999-12-07 2002-09-04 Novartis AG Antagonistes de l'integrine vla-4
JP2003519697A (ja) 1999-12-28 2003-06-24 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸器疾患の処置に有用な非ペプチド系のvla−4依存性細胞結合阻害薬
DE10019755A1 (de) * 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
GB2367816A (en) 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
TWI389904B (zh) 2006-02-27 2013-03-21 Elan Pharm Inc 抑制由vla-4所調節的白血球黏附之嘧啶磺醯胺化合物
EP2510941A3 (fr) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Procédés de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
HUP0101701A3 (en) * 1997-12-23 2003-02-28 Aventis Pharma Ltd West Mallin Substituted betha-alanines and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
NO20003694D0 (no) 2000-07-19
WO1999037605A1 (fr) 1999-07-29
CN1294576A (zh) 2001-05-09
AU2829299A (en) 1999-08-09
EP1049665A1 (fr) 2000-11-08
BR9907733A (pt) 2000-10-17
AU746174B2 (en) 2002-04-18
ID26665A (id) 2001-01-25
HUP0100336A2 (hu) 2001-07-30
KR20010034317A (ko) 2001-04-25
HUP0100336A3 (en) 2002-11-28
JP2002501039A (ja) 2002-01-15
NO20003694L (no) 2000-09-20
EE200000428A (et) 2001-12-17
CA2318639A1 (fr) 1999-07-29
JP4564654B2 (ja) 2010-10-20

Similar Documents

Publication Publication Date Title
DE69909613D1 (en) Bicyclische hydroxamsäurederivate
PL341642A1 (en) Novel macrolydes
EP1092069A4 (fr) Modele ameliore de montant
DE59903023D1 (en) Perorale wirkstoff-suspension
HU9903216D0 (en) Substituted benzamide
GB9826359D0 (en) Novel receptors
IL137329A0 (en) Vla-4 antagonists
EP1068213A4 (fr) Nouveaux siloxanes amino-organo-fonctionnels
GB2337049B (en) Trisresorcinyltriazines
PL347397A1 (en) Substituted 3-aryl-pyrazoles
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
DE59900471D1 (en) Inchbremseinrichtung
DE69912430D1 (en) Hydroformylierungsreaktionen
PL345866A1 (en) Substituted cyclooctadepsipeptides
GB2336996B (en) Multi-desk
GB0005589D0 (en) New
GB9826962D0 (en) Fastenings
GB9816429D0 (en) Fastenings
GB9901323D0 (en) Freeface 1
PL341899A1 (en) Vla-4 antagonists
GB2339852B (en) Airjack
TW407677U (en) Form
GB0028459D0 (en) Glor 2
GB9916299D0 (en) Dogex 1
HK1033825A (en) Vla-4 antagonists